Meet CHECKEYE at MEDICA 2025!
Retinopathy Prevention. Early Detection of Chronic Diseases.
Schedule an appointment with us for MEDICA 2025 in Düsseldorf!
Register now!
Register here for your free retinal screening.
Register now
Fill out our short registration from and we will contact you to arrange an appointment with us for MEDICA.
Get your free ticket
As soon as an appointment has been made, we will send you your ticket.
Meet us at MEDICA
Visit our stand at the agreed time. We look forward to meet you!
DON’T IGNORE WHAT YOUR EYES CAN REVEAL!
TRY CHECKEYE’S CLOUD-BASED SOLUTION TO DETECT EARLY SIGNS OF CHRONIC DISEASES. GET YOUR FREE RETINAL SCREENING AND HEALTH REPORT AT OUR MEDICA BOOTH!
ABOUT US
CheckEye is a Ukrainian health-tech startup founded in early 2022, headquartered in Kyiv. The company develops a cloud-based AI/ML platform for the early detection of chronic diseases via retinal imaging – starting with diabetic retinopathy. Its mission is to make screening accessible, affordable and scalable, even in non-specialist settings such as opticians, pharmacies or remote clinics.
What We Do & Technology
The CheckEye platform allows a fundus (retinal) photograph to be uploaded to a cloud-based system, where AI algorithms analyse the image for signs of disease and generate a screening result within seconds (often under 60 seconds). Initially focused on detecting Diabetic Retinopathy (a major complication of diabetes and leading cause of vision loss), the roadmap extends to screening for dozens of other chronic diseases (40+ conditions including vascular, cardiovascular and neuro-degenerative disorders). The platform enables non-medical staff in outpatient settings to capture the image, upload it, and the system helps triage which patients need specialist attention – thereby reducing load on specialists, shortening waiting times and broadening access.
Impact, Achievements & Expansion
CheckEye has carried out mass screening programmes even under challenging conditions (e.g., Ukraine under martial law) – making it the first AI-based platform in Europe to conduct nationwide diabetic retinopathy screening. It has achieved high accuracy in real-world pilots (e.g., reported sensitivity & specificity rates, and entry into Germany via a pilot with Gesundheitskiosk24 in Heidelberg). The company has also been recognised internationally (winner of the EIT Health InnoStars Awards) and is actively expanding into European markets. With funding of several hundred thousand dollars/grants, it is scaling product localisation, regulatory work, and partnership-deployment across pharmacies, clinics and public health systems.
